Labcorp Offering Test For Early Indication Of Neurodegenerative Disease  

Labcorp is now offering a test for glial fibrillary acidic protein (GFAP), a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological injuries. The test will be offered commercially across the U.S. ;

The company said its GFAP test uses a sensitive immunoassay technology to measure the presence of GFAP from a simple blood draw. The biomarker test will;offer physicians a more efficient pathway to assess the presence and progression of neurodegenerative diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and injuries such as traumatic brain injury (TBI). ;

The GFAP test expands . . .